Target
RAF kinase
23 abstracts
Abstract
A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799544 (ARRY-134) as a single agent and in combination with PF-07799933 BRAF dimer inhibitor, in participants 16 years and older with advanced solid tumors.Org: Chercheur clinicien centre de recherche CHU de Québec, Department of Medical Oncology, McGill University Health Centre, Division of Neuro-Oncology, NewYork-Presbyterian/Columbia University Medical Center,
Abstract
Sorafenib plus hepatic arterial infusion of oxaliplatin and fluorouracil vs sorafenib plus transarterial chemoembolization for advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase III trial (SHATA-001).Org: Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China, Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China,
Abstract
SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A randomized phase 3 trial.Org: Department of Hepatobiliary Pancreatic and Splenic Surgery, Baoji Central Hospital, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, The First Affiliated Hospital of Bengbu Medical University,
Abstract
Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Initial safety and efficacy of phase 1b/2 study (RAMP 205).Org: Virginia Mason Hospital and Medical Center, Verastem Oncology,
Abstract
Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.Org: Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany, Chinese University of Hong Kong, Hong Kong, China, Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China, Department of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin, China, Department of Interventional Radiology, Hunan Cancer Hospital, Changsha, China, Department of Oncology, Fujian Medical University Union Hospital, Fuzhou, China, Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China, Department of General Surgery, Anhui Provincial Hospital, Hefei, China, Department of Medical Oncology, Sichuan Cancer Hospital and Institute/The Affiliated Cancer Hospital School of Medicine, UESTC, Chengdu, China, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Liver Cancer Center, Guangzhou, China, Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, State Autonomous Budgetary Healthcare Institution, Republican Clinical Oncological Dispensary of the MoH of Republic Bashkortostan, Ufa, Russian Federation, Department of Infectious Disease and Hepatology, Wroclaw Medical University, and Centrum Badań Klinicznych P.Napora, Wroclaw, Poland, Department of Liver and Pancreas Gland Oncosurgery, Communal Non-profit Enterprise "Regional Center of Oncology", Kharkiv, Ukraine, Jiangsu Hengrui Pharmaceuticals, Co., Ltd, Shanghai, China, National Taiwan University Hospital, Taipei, Taiwan, Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX, Cancer Center of Nanjing, Jinling Hospital, Nanjing, China,
Abstract
Characterization of mutational signatures demonstrating adaptive mutability post anti-EGFR therapy in a real-world metastatic colorectal cancer cohort.Org: Department of Gastrointestinal Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, Houston, TX, Guardant Health, Redwood City, CA, Guardant Health, Inc., Redwood City, CA,
Abstract
The efficacy of atezolizumab plus bevacizumab in the treatment of unresectable hepatocellular carcinoma in cirrhotic and non-cirrhotic patients.Org: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico,
Abstract
Efficacy and safety analysis of donafenib combined with transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: A prospective, single-arm, single center, phase II clinical study.Org: Intervention Ward One,
Abstract
The efficacy and safety of donafenib combined with transcatheter arterial chemoembolization and anti-PD-1 antibodies as first-line therapy for hepatocellular carcinoma: A retrospective study.Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Department of Interventional Radiology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).Org: The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, National Cancer Research Institute (NCRI), University of Virginia, Charlottesville, VA, USA, University Hospitals Leuven, Leuven, Belgium, Institut du Cancer de Montpellier (ICM) Val d'Aurelle Parc Euromedecine,
Abstract
NeoTACE: A multicenter, randomized study evaluating the efficacy and safety of neoadjuvant HAIC for TACE plus donafenib in BCLC B stage hepatocellular carcinoma outside of up-to-seven.Org: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital & Institute,
Abstract
RAF-inhibitor rechallenge therapy in BRAF aberrated pan-cancers: RE-RAFFLE study.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy/ University of Texas MD Anderson Cancer Center,
Abstract
Phase II study on safety and efficacy of NMS-01940153E, an MPS1 inhibitor with first-in-class potential, in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy.Org: Humanitas University, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milano), Italy, IRCCS Humanitas Research Hospital, Rozzano, Italy, Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy, Hospital Clínic Barcelona,
Abstract
Geographical and baseline clinical characteristics of participants enrolled in hepatocellular carcinoma (HCC) trials: Analysis of US FDA approvals.Org: FDA/CDER, U.S. Food and Drug Administration, US Food and Drug Administration, Oncology Center of Excellence, Office of New Drugs,
Abstract
Clinical efficacy and safety of immune checkpoint inhibitor in combination with regorafenib therapy as second⁃line regimen for patients with unresectable hepatocellular carcinoma.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Shandong Cancer Hospital and Institute, Jinan, shandong, China, Shandong Cancer Hospital and Institute, Jinan, China,
Abstract
LOGGIC/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.Org: Hopp Children’s Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ), Children's National Hospital, Washington, DC, Seattle Children’s Hospital, Orlando Health Arnold Palmer Hospital for Children,
Abstract
Sequential therapy versus first-line tyrosine kinase inhibitor plus immune checkpoint inhibitor therapy for unresectable hepatocellular carcinoma.Org: The First Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, the Naval Medical University, Shanghai, China, Department of Special Treatment I and Liver Transplantation, Eastern Hepatobiliary Surgery Hospital, the Naval Medical University, Shanghai, China, Shanghai Hongkou Center for Disease Control and Prevention, Shanghai, China, Department of Vascular Surgery, Changzheng Hospital, the Naval Medical University, Shanghai, China, The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, the Naval Medical University, Shanghai, China,
Abstract
Sintilimab combined with bevacizumab biosimilar as a conversion therapy in potentially resectable intermediate-stage hepatocellular carcinoma (HCC): Updated results of a phase II trial.Org: Department of Liver Surgery & Transplantation Center, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China, Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, China, Zhongshan Hospital Liver Cancer Institute, Shanghai, China, Department of Pathology，Zhongshan Hospital, Fudan University, Shanghai, China, Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China,
Abstract
RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).Org: Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, DC, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, Lecanto, FL,
Abstract
Effect of dual properties of regorafenib in osteosarcoma on tumor progression and bone parameters in mouse preclinical models.Org: ICO Institut de Cancerologie de l'Ouest, Department of Basic Studies, Faculty of Odontology, University of Antioquia, Institut de Cancérologie de l'Ouest (ICO)-site René Gauducheau, Hephaistos Pharma, Léon Bérard Centre,
Abstract
Introducing yttrium-90 radioembolization to atezolizumab and bevacizumab regimen for intermediate and advanced stage hepatocellular carcinoma: A preliminary report of safety and effectiveness.Org: University of Chicago Medical Center, Chicago, IL, Chicago, IL, Ascension Providence Hospital, Southfield, MI, University of Chicago,
Abstract
Identification of clinically actionable biomarkers in an Indian cancer cohort using comprehensive genomic profiling (CGP): An institutional experience.Org: Triesta Sciences, HCG Cancer Center Mumbai, Strand Life Sciences,
Abstract
Treatment patterns post atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: Real-world analysis at Veterans Health Administration comparing lenvatinib vs. sorafenib.Org: Univeristy of Texas Health Science Center San Antonio, San Antonio, TX, University of Texas Health Science Center at San Antonio, San Anonio, TX, The University of Texas Health Science Center-San Antonio,